Biology Reference
In-Depth Information
Beavo JA, Conti M, Heaslip RJ (1994) Multiple cyclic nucleotide phosphodiesterases. Mol
Pharmacol 46:399-405
Benotti JR, Grossman W, Braunwald E, Davolos DD, Alousi A (1978) Hemodynamic assessment
of amrinone. N Engl J Med 299:1373-1377
Beume R, Kilian U, Brand U, H
afner D, Eltze M, Flockerzi D (1993) The bronchospasmolytic
effects of the PDEIII/IV inhibitors B9004-70 and zardaverine - dependency on the route of
administration in guinea pigs. Am Rev Respir Dis 174:A184
Boero S, Silvestri M, Sabatini F, Nachira A, Rossi GA (2006) Inhibition of human lung fibroblast
functions by roflumilast N-oxide. Eur J Respir (Suppl) 662s:P3845, abstract
Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, Osterloh IH, Gingell C
(1996) Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for
the treatment of penile erectile dysfunction. Int J Impot Res 8:47-52
Brindley GS (1982) Intracavernous injection of papaverine for erectile failure. Lancet 2:938
Brindley GS (1986) Pilot experiments on the actions of drugs injected into the human corpus
cavernosum penis. Br J Pharmacol 87:495-500
Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R (2001) In vivo efficacy in
airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp
Ther 297:280-290
Burgin AB, Magnusson OT, Singh J, Witte P, Staker BL, Bjornsson JM, Thorsteinsdottir M,
Hrafnsdottir S, Hagen T, Kiselyov AS, Stewart LJ, Gurney ME (2010) Design of
phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved
safety. Nat Biotechnol 28:63-70
Burkman AM (1982) Assessment of emetic and antiemetic activity. J Pharmacol Meth 8:165-171
Butcher RW (1984) Phosphodiesterase after 20 years: an Introduction. Adv Cycl Nucl Protein
Phos Res 16:1-12
Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ, M2-124 and
M2-125 study groups (2009) Roflumilast in symptomatic chronic obstructive pulmonary
disease. Two randomized clinical trials. Lancet 374:685-94
Campbell SF (2000) Science, art and drug discovery: a personal perspective. Clin Sci 99:255-260
Cantin AM, Hanrahan JW, Bilodeau G, Ellis L, Dupuis A, Liao J, Zielenski J, Durie P (2006)
Cystic fibrosis transmembrane conductance regulator function is suppressed in cigarette
smokers. Am J Respir Crit Care Med 173:1139-44
Cervin A, Lindgren S (1998) The effect of selective phosphodiesterase inhibitors on mucociliary
activity in the upper and lower airways in vitro. Auris Nasus Larynx 25:269-76
Chikanza IC, Jawed SJ, Blake DR, Perrot S, Menkes CI, Barnes CG, Perry JD, Wright MG (1996)
Treatment of patients with rheumathoid arthritis with RP73401 phosphodiesterase type IV
inhibitor. Arthritis Rheum 39:282
Christensen SB, DeWolf WE, Ryan MD, Torphy TJ (1996) Molecular aspects of inhibitor
interaction with PDE4. In: Schudt C, Dent G, Rabe KF (eds) Phosphodiesterase inhibitors.
Acedemic, London
Churg A, Cosio M, Wright JL (2008) Mechanism of cigarette smoke-induced COPD: insights from
animal models. Am J Physiol Lung Cell Mol 294:L612-L631
Cockroft DW (1983) Mechanism of perennial allergic asthma. Lancet 322:253-256
Cohen NA, Zhang S, Sharp DB, Tamashiro E, Chen B, Sorscher EJ, Woodworth BA (2009)
Cigarette smoke condensate inhibits transepithelial chloride transport and ciliary beat
frequency. Laryngoscope 119:2269-2274
Compton CH, Gubb J, Nieman R, Edelson J, Ohad A, Bakst A, Ayres JG, Creemers JP, Schultze-
Werninghaus G, Brambilla C, Barnes NC (2001) Cilomilast, a selective phosphodiesterase-4
inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised,
dose-ranging study. Lancet 358:265-270
Conti M, Beavo J (2007) Biochemistry and physiology of cyclic nucleotide phosphodiesterases:
essential components in cyclic nucleotide signaling. Annu Rev Biochem 76:481-511
€
